Please ensure Javascript is enabled for purposes of website accessibility

Welcome to Regulatory Rapporteur. This site uses cookies. Read our policy.

  • Skip to main content
  • Skip to navigation
Site name
topra-logo

The Organisation for Professionals in Regulatory Affairs
Site name
Mast navigation
  • Become a member
  • Sign in
Search our site
Menu
Close menu
  • Regulatory Rapporteur - October 2024
  • Pharmaceuticals
    • Back to parent navigation item
    • Pharmaceuticals
    • Artificial intelligence
    • ATMP
    • Biologics
    • Chemistry, manufacturing and controls
    • Clinical trials
    • Non-clinical development
    • Oncology
    • Product information
    • Regulatory procedures
  • Veterinary
  • Medical devices
    • Back to parent navigation item
    • Medical devices
    • Combination products
    • In-vitro diagnostics
    • Software
    • Artificial intelligence
  • Industry news
    • Back to parent navigation item
    • Industry news
    • Industry news
      • Back to parent navigation item
      • Industry news
      • Read latest news
      • Video
  • Commentary
    • Back to parent navigation item
    • Commentary
    • Editorials
    • Letters to the Editor
    • Podcasts
  • Collections
    • Back to parent navigation item
    • Collections
    • Interviews
    • Symposium 2024
      • Back to parent navigation item
      • Symposium 2024
      • Annual lecture
    • Symposium 2023
      • Back to parent navigation item
      • Symposium 2023
      • Annual lecture
    • Symposium 2022
      • Back to parent navigation item
      • Symposium 2022
      • Annual lecture
    • Symposium 2021
      • Back to parent navigation item
      • Symposium 2021
      • Annual lecture
    • CPD supplements
      • Back to parent navigation item
      • CPD supplements
      • 2021/2022
      • 2020
      • 2019
  • JOIN TOPRA
  • topra-logo

    The Organisation for Professionals in Regulatory Affairs
  • Regulatory Rapporteur - October 2024
  • Pharmaceuticals
      • Artificial intelligence
      • ATMP
      • Biologics
      • Chemistry, manufacturing and controls
      • Clinical trials
      • Non-clinical development
      • Oncology
      • Product information
      • Regulatory procedures
    • RR-Nov-2024-Half-Cover
      November 2024 – Contents: Human medicines sessions
    • DADI_compressed
      Revolutionising compliance with DADI: a new frontier for digital integration
    • RR-Oct-2024-Half-Cover
      October 2024 – Contents
  • Veterinary
    • RR-Nov-2024-Half-Cover
      November 2024 – Contents: Veterinary medicines sessions
    • SUSIMPERATIVE_compressed
      The sustainability imperative for the healthcare sector
    • AdobeStock_537705324
      New data protection for maximum residue limits
    • AdobeStock_294025271
      EMA platform to monitor use of antimicrobials
  • Medical devices
      • Combination products
      • In-vitro diagnostics
      • Software
      • Artificial intelligence
    • RR-Nov-2024-Half-Cover
      November 2024 – Contents: Medical devices/IVDs sessions
    • elabels image_compressed
      E-labelling: revolutionising the labelling landscape
    • AdobeStock_841428142_compressed
      New approach methodologies for the biological safety assessment of medical devices
  • Industry news
      • Industry news
        • Read latest news
        • Video
    • Doctor holding pills
      ​FDA proposes to remove oral phenylephrine in selected drugs
    • AdobeStock_84467162_small
      New cancer drug approved by MHRA
    • AdobeStock_663473209-min
      New guidance for wholesalers and manufacturers following Windsor Framework
  • Commentary
      • Editorials
      • Letters to the Editor
      • Podcasts
    • Michael Kipping
      Improving health outcomes through regulatory excellence
    • AdobeStock_971129498_SMALL
      Chemistry, manufacturing and controls: accelerating development and boosting innovation
    • AdobeStock_922131460_small
      The complexities of botanical regulation
  • Collections
      • Interviews
      • Symposium 2024
        • Annual lecture
      • Symposium 2023
        • Annual lecture
      • Symposium 2022
        • Annual lecture
      • Symposium 2021
        • Annual lecture
      • CPD supplements
        • 2021/2022
        • 2020
        • 2019
    • Banner_new
      Streamline medical device compliance with BSI Compliance NavigatorSponsored by The UK's National Standards Body
    • AdobeStock_59790119
      The Olaratumab experience
    • AdobeStock_207448226
      Qualification of stride velocity endpoint in Duchenne Muscular Dystrophy
  • JOIN TOPRA
  • More from navigation items

Non-Clinical Development Stories

  • biopharm comp

    Nonclinical immunogenicity evaluation in toxicology studies of biopharmaceuticals

    2021-12-23T10:53:00+00:00By Sebastian Joseph

  • What is Regulatory Affairs?
  • TOPRA Membership
  • Regulatory Rapporteur Editorial Board
  • Regulatory Rapporteur Editorial Area
  • Future Focus Topics
  • FAQs
  • Glossary
  • Privacy Policy
  • ISSN 2755-5070 (online)

    ISSN 1742-8955 (print - legacy)

Regulatory Rapporteur

The peer-reviewed journal, published 11 times per year and available free to TOPRA members.

Follow TOPRA
topra-logo

The Organisation for Professionals in Regulatory Affairs

TOPRA office
TOPRA Publishing, 6th Floor, 3 Harbour Exchange, South Quay, London E14 9GE, UK
Tel: +44 (0) 20 7510 2560
Email: publications@topra.org

TOPRA AISBL
Blvd du Souverain 280, 1160 Brussels, Belgium
Tel: +32 (0) 2 808 72 70

  • Contact us
  • Copyright © 2015-2024 The Organisation for Professionals in Regulatory Affairs Ltd. t/a Regulatory Rapporteur - All rights reserved

Site powered by Webvision Cloud